{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Emerging Biotech Leader","title":"Pioneering With Patients First - Kate Goldstein : 18","html":"","width":"100%","height":180,"duration":1354,"description":"“A lot of the work is in asking ‘how do we distill this down into the simplest, most digestible narrative that feels obvious when you hear it back?’” Kim Kushner, Chief Business Officer, SSI Strategy. Episode 18 of the Emerging Biotech Leader welcomes a new voice to the show: Kate Goldstein, Senior Vice President of SSI. Fresh off the heels of Episode 17, Kate, Kim, and Ramin continue to unpack more value from Luminopia’s founding story and subsequent growth. If you haven’t had a chance to listen to that yet, here’s the link. One of the most powerful components of a biotech is its value story. But getting clear on that isn’t always easy. In this new era of biotechs and clinical development, the value story and narrative isn’t just for investors: it's for other stakeholders like physicians and patients, too. As stakeholders get involved earlier in the process to increase patient-centricity, they want to understand the value as well. In fact, it's almost table stakes.  This begs the question, how do you approach this when bringing a novel modality to market? How does an unmet need influence the value story? How were Scott and his team able to get theirs so clear? What does patient centricity have to do with product market fit? These are a few clues as to what you’ll be hearing during this episode. Listen along to pick up more highlights, approaches, and thoughts. Uncovering The Obvious Is Not That ObviousKim kicked off the interview with a question for Kate first. How was Luminopia able to be so clear with its value story compared to other biotechs with traditional modalities? Was it Scott, their CEO + Co-Founder’s ability to tell a captivating story? Was it the fact they were disrupting a space overdue for innovation? Was it the focus on the patient, front and center?Kate quickly weighed in: the story resonated with more than one audience. “I think one of the ways that we're really going to get truly novel modalities to market for the first time is by telling the...","thumbnail_url":"https://img.transistorcdn.com/ifry0mqC60CO4NUZn9GSCTvcoZ9yKEWu4twnqKmJQQ0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS80NzEy/MTZiMmZlODIyZDI4/OTliMGJiOWQ0ZDUx/MDhmNi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}